By G HossainPosted on June 2, 2025Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab. Amid Rough Waters, Regeneron Puts Nearly $2B on the Line For Chinese Obesity Drug Post navigation Sanofi Inks $9.5B Blueprint Buyout to Expand Rare Disease PortfolioArt of Accounting: My 600th and final column